Curaxins are synthetic small molecules intended to simultaneously target major cell stress response pathways that are frequently deregulated in cancer.
Incuron CEO Andrei Leonov said this prestigious Skolkovo grant significantly raises the profile of their work with Curaxins in oncology.
"Moreover, it may enable us to explore additional potential applications of this novel class of therapeutic agents," Leonov said.